## Wei-Min She

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6502803/publications.pdf

Version: 2024-02-01

1477746 1473754 9 238 9 6 citations h-index g-index papers 10 10 10 440 citing authors docs citations times ranked all docs

#	Article	IF	CITATIONS
1	Entecavirâ€induced interferonâ€î»1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virusâ€related liver cirrhosis. Journal of Viral Hepatitis, 2021, 28, 795-808.	1.0	2
2	Pegâ€interferon alpha addâ€on Tenofovir disoproxil fumarate achieved more HBsAg loss in HBeAgâ€positive chronic hepatitis B naìve patients. Journal of Viral Hepatitis, 2021, 28, 1381-1391.	1.0	4
3	Serum amyloid A levels in patients with liver diseases. World Journal of Gastroenterology, 2019, 25, 6440-6450.	1.4	18
4	Type 3 innate lymphoid cell: a new player in liver fibrosis progression. Clinical Science, 2018, 132, 2565-2582.	1.8	41
5	HMGB1-induced autophagy: a new pathway to maintain Treg function during chronic hepatitis B virus infection. Clinical Science, 2017, 131, 381-394.	1.8	30
6	Activated hepatic stellate cells directly induce pathogenic Th17 cells in chronic hepatitis B virus infection. Experimental Cell Research, 2017, 359, 129-137.	1.2	14
7	IL-10-producing regulatory B-cells suppressed effector T-cells but enhanced regulatory T-cells in chronic HBV infection. Clinical Science, 2016, 130, 907-919.	1.8	81
8	3, 3′-diindolylmethane alleviates steatosis and the progression of NASH partly through shifting the imbalance of Treg/Th17 cells to Treg dominance. International Immunopharmacology, 2014, 23, 489-498.	1.7	47
9	Correlation between viral load and liver cirrhosis in chronic hepatitis B patients. Frontiers of Medicine in China, 2009, 3, 271-276.	0.1	1